Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies

[1] Chacra AR(2005)An algorithm for the treatment of type 2 diabetes in Latin America Diabetes Obes Metab 7 148-160

[2] Davidson JA(2011)Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes Diabetes Care 34 S251-S257

[3] Diaz J(2007)The role of gut hormones in glucose homeostasis J Clin Invest 117 24-32

[4] Escalante-Pulido M(2008)Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase–4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes Clin Ther 30 499-512

[5] Litwak LE(2008)Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase–4 inhibitor alogliptin in healthy male subjects Clin Ther 30 513-527

[6] Mestman JH(2011)An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development Contemp Clin Trials 32 324-332

[7] More L(2007)New therapeutic options for treating type-2 diabetes: a review of insulin analogs and premixed insulin analogs J Natl Med Assoc 99 357-367

[8] Violante RM(2012)Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis Diabetes Obes Metab 14 1061-1072

[9] Holst JJ(2009)Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycemia Diabetes Obes Metab 11 1145-1152

[10] Knop FK(2011)Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials BMJ 342 d4002-1096

[1] Chacra AR(2005)An algorithm for the treatment of type 2 diabetes in Latin America Diabetes Obes Metab 7 148-160

[2] Davidson JA(2011)Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes Diabetes Care 34 S251-S257

[3] Diaz J(2007)The role of gut hormones in glucose homeostasis J Clin Invest 117 24-32

[4] Escalante-Pulido M(2008)Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase–4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes Clin Ther 30 499-512

[5] Litwak LE(2008)Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase–4 inhibitor alogliptin in healthy male subjects Clin Ther 30 513-527

[6] Mestman JH(2011)An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development Contemp Clin Trials 32 324-332

[7] More L(2007)New therapeutic options for treating type-2 diabetes: a review of insulin analogs and premixed insulin analogs J Natl Med Assoc 99 357-367

[8] Violante RM(2012)Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis Diabetes Obes Metab 14 1061-1072

[9] Holst JJ(2009)Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycemia Diabetes Obes Metab 11 1145-1152

[10] Knop FK(2011)Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials BMJ 342 d4002-1096